| abstract |
The present invention relates to novel, specific binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), preferably a mutein of lipocalin, more preferably lipocalin 2 (Lcn2 or NGAL). The present invention also relates to nucleic acid molecules encoding such proteins as well as methods and uses for the production of such proteins and nucleic acid molecules. Accordingly, the present invention also relates to pharmaceutical and/or diagnostic compositions comprising such lipocalins, including the use of these proteins. |